Does Subclinical Hypothyroidism Affect Dynamic Thiol / Disulfide Homeostasis and Ischemia-modified Albumin Levels in Children?

Serkan Tursun¹, Aysegul Alpcan¹, Ayca Torel Ergur², Irfan Karahan³, Salim Neselioglu⁴ and Ozcan Erel⁴

¹Department of Pediatrics, Faculty of Medicine, Kirikkale University, Turkey
²Department of Pediatrics Endocrinology, Faculty of Medicine, Ufuk University, Turkey
³Department of Internal Medicine, Faculty of Medicine, Kirikkale University, Turkey
⁴Department of Medical Biochemistry, Faculty of Medicine, Yildirim Beyazit University, Turkey

ABSTRACT

Objective: To determine the effects of subclinical hypothyroidism on oxidative stress in children.

Study Design: A cross-sectional study.

Place and Duration of Study: Department of Paediatrics, Paediatric Endocrinology, and General Outpatient Clinics, Kirikkale University, School of Medicine, from May 2017 to October 2018.

Methodology: This study included 92 subjects aged between 2 and 18 years. The subjects were divided into two groups. Forty-seven children with subclinical hypothyroidism and 45 healthy controls were evaluated. In order to evaluate oxidative damage, native thiol, total thiol, disulfides, their ratios, and ischemia-modified albumin (IMA) levels were compared between the two groups. The relationship between TSH and IMA levels was assessed.

Results: Age and gender were not significantly different in the two groups. Native thiol, total thiol, disulfides and their ratios were similar in the two groups. Ischemia-modified albumin levels were significantly higher in the patient group than the controls (p<0.001). There was no correlation between TSH and IMA levels in the patient group (r=0.069, p=0.645).

Conclusion: Subclinical hypothyroidism may be related to the impairment of IMA, and have a neutral effect on thiol/disulfide balance. Further research is needed to explain the effects of oxidative stress in subclinical hypothyroidism.

Key Words: Subclinical hypothyroidism, Childhood, Oxidative stress.

How to cite this article: Tursun S, Alpcan A, Ergur AT, Karahan I, Neselioglu S, Erel O. Does Subclinical Hypothyroidism Affect Dynamic Thiol / Disulfide Homeostasis and Ischemia-modified Albumin Levels in Children?. J Coll Physicians Surg Pak 2020; 30(07):726-729.

INTRODUCTION

Subclinical hypothyroidism (SHT) is a condition with no specific symptoms, which is characterised by an elevated thyroid-stimulating hormone (TSH) level along with normal free triiodothyronine (fT3) and free thyroxine (fT4) levels. Whereas, the prevalence of SHT is approximately 4-20% in adults, it is less than 10% in children. Subclinical hypothyroidism is considered a risk factor for overt hypothyroidism, atherosclerosis, and cardiovascular diseases. Thyroid hormones also have a pivotal role in neurological maturation, cardiovascular functions, and linear growth. Subclinical hypothyroidism may affect these conditions and have relevant clinical complications.

Hypothyroidism can cause oxidative stress by impairing the balance between oxidant and antioxidant capacities.

Thiols are buffers and act as antioxidants. Thiols include sulfhydryl groups that can reduce oxidant agents. This antioxidant mechanism protects the organism from the harmful effects of oxidative damage.

Thiols are converted to disulfides during the reaction and may be converted into thiol groups again. These reactions are termed as the dynamic thiol/disulfide homeostasis. Thiol/disulfide balance is an indicator of oxidative stress. Ischemia-modified albumin (IMA) is a novel biomarker reflecting oxidative damage and ischemia. Ischemia-modified albumin is related to cardiac ischemia as well as non-cardiac pathologies such as renal diseases, peripheral artery disease, and hepatic disease.

This study aimed to determine the effects of subclinical hypothyroidism on thiol/disulfide balance and IMA levels.

METHODOLOGY

This study included 92 patients aged between 2 and 18 years, who were admitted to the Department of Paediatric Endocrinology, Kirikkale University School of Medicine, Turkey for TSH elevation during examinations and routine controls. Patients
with any systemic and/or infectious disease, other endocrinopathies, inflammatory conditions and/or medication use were excluded. A detailed physical examination and anthropometric measurements were performed in all children. The chronological age and body mass index (BMI) were recorded. The reference BMI curves for Turkish children were utilized.² BMI was calculated with the formula: weight (kg)/height x height (metres).

SHT was diagnosed on the basis of normal fT4 and fT3 levels along with increased TSH level (mild: 4.5-10 severe >10mIU/L).³ This cross-sectional designed study included 92 children aged between 2 and 18 years. Forty-seven patients with SHT and 45 healthy subjects (the control group) were evaluated. The control group was matched with the study group for age and gender, and the laboratory parameters (biochemical and hormone assays) were within normal limits in the control group. Total thiol, native thiol, disulfide, disulfide/total thiol, disulfide/native thiol, native thiol/total thiol levels, and ischemia-modified albumin levels were compared between the two groups. The parents of the patients gave informed consent for study participation.

Specimens were collected in the early morning, for the measurement of thiol/disulfide homeostasis parameters. All samples were centrifuged for 10 min at 1500 rpm to pick out the serum. Serum dynamic thiol/disulfide homeostasis and ischemia-modified albumin levels were studied with the spectrophotometric method,⁴ an automated clinical chemistry analyser.

Ischemia-modified albumin measurement was performed by a colorimetric assay method that was described by Bar-Or et al.⁵ This method is based on albumin binding to exogenous cobalt. Ischemia-modified albumin results were expressed in absorbance units (ABSUs). The thiol/disulfide parameters and IMA were analysed at Faculty of Medicine, Biochemistry Laboratory, Yıldırım Beyazıt University.

All data were analysed using IBM SPSS version 25. Shapiro-Wilk test was used to test the normality of data distribution. Quantitative variables with normal distribution were expressed as mean ± standard deviation and those with non-normal distribution as median (IQR 1st quartile: Q1- 3rd quartile: Q3). Independent samples t-test or Mann-Whitney U-test was used to compare two means of quantitative data. Categorical variables were expressed as frequency and percentage. Chi-square test was used for categorical variables. Pearson’s correlation analysis was used to analyse correlations. The p-values <0.05 were considered statistically significant.

This study was approved by the Institutional Review Board. (Date: 16.05.2017 Number: 12/23)

RESULTS
The mean age of participants was 11.52±3.99 years. The study population consisted of 47 girls (51.1%) and 45 boys (48.9%). General characteristics and laboratory values of the patient and control groups were shown in Table I.

There was no statistically significant difference between the two groups with respect to the levels of total thiol level, native thiol level, disulfide level, and their ratios including disulfide/total thiol, disulfide/native thiol, native thiol/total thiol ratios. Ischemia-modified albumin levels were higher in the SHT group than the control group (Table II). There was no correlation between TSH and IMA levels in the SHT group (r=0.069, p=0.645).

DISCUSSION
Oxidative stress has a key role in various cardiovascular and chronic diseases, and many prospective studies have shown such association.¹² The present study showed that patients with SHT and healthy subjects had similar dynamic thiol/disulfide parameters. But the patients had higher IMA levels than the healthy controls. IMA may reflect atherogenesis and vascular system injury via oxidative stress.¹³ It is a good biochemical marker for early ischemia such that its level increases in acute coronary syndromes,¹⁴ acute heart failure,¹⁵ liver cirrhosis,¹⁶ diabetes mellitus,¹⁷ malignancies,¹⁸ among other disorders. Doğan et al. showed that patients with SHT had higher levels of atherogenic lipids than healthy controls; there was also a significant relationship between TSH levels and the levels of atherogenic lipids.¹⁹ They emphasised that SHT may create a potential risk for atherogenesis.

Reddy et al. found a higher IMA level in patients with overt and subclinical hypothyroidism than euthyroid controls, and also a significant correlation between TSH and IMA levels in overt hypothyroidism.²⁰ However, there was no similar association in SHT patients. They speculated that hypothyroidism may increase oxidative damage to lipids and proteins. Their findings support this data.
Does subclinical hypothyroidism affect dynamic thiol / disulfide Homeostasis and ischemia-modified albumin levels in children?

Erem et al. showed that levothyroxine treatment might mitigate lipid peroxidation, oxidative damage, and atherogenesis.\textsuperscript{21} They studied overt and subclinical hypothyroidism patients. Malondialdehyde (MDA) and IMA levels were evaluated before and after hormone replacement therapy. Malondialdehyde level was reduced by treatment, but the IMA level remained unchanged. They suggested that MDA, but not IMA, can be considered as a reliable marker of oxidative damage.

Another study found different results than ours and other mentioned studies. They compared IMA and albumin-adjusted IMA in hyperthyroid, euthyroid and hypothyroid groups. IMA levels were significantly lower in the hypothyroid subjects than the other groups. They attributed this finding to studying with albumin-adjusted IMA, hypoalbuminemia, and hypometabolic state of hypothyroidism.\textsuperscript{22} All mentioned studies were designed in the adult populations; whereas, the population of this study was composed of children.

Uçaktürk et al. studied SHT and dynamic thiol/disulfide balance but not IMA in children.\textsuperscript{23} Their data support the present findings in that they found no significant difference between children with non-autoimmune SHT and the healthy group with respect to dynamic thiol/disulfide balance. The investigators addressed the need for future studies to assess oxidative damage in patients with non-autoimmune SHT in childhood.

Another study on thiol/disulfide metabolism and subclinical hypothyroidism in adults showed that subclinical hypothyroidism caused disulfide formation. That study also found a correlation between antibody levels and thiol oxidation. The authors of that study stated that the mechanism was not clear. Although their data contradict with our findings, one must consider that that study was conducted with adults.\textsuperscript{24} Cheserek et al. studied total antioxidant capacity in SHT.\textsuperscript{25} Total antioxidant capacity was found similar in SHT and euthyroid controls. The two above-mentioned studies support the present data.

This study has several limitations. The sample size is small, and the levels of thyroid antibodies were unknown. Moreover, the study population was heterogeneous. Furthermore, the study design was cross-sectional and follow-up of thyroid hormone levels was lacking. The status of thyroid antibody levels was not completely available. However, the present study may be the first to evaluate IMA in children with SHT. This issue may be important for childhood thyroid diseases.

**CONCLUSION**

This study showed that subclinical hypothyroidism did not affect dynamic thiol/disulfide balance. However, the level of ischemia-modified albumin, a novel ischemic marker, was higher than healthy controls. Subclinical hypothyroidism may be related to the impairment of IMA, and have a neutral effect on thiol/disulfide balance. Further investigations are needed to clarify the mechanism of the relationship between oxidative damage, ischemia, and subclinical hypothyroidism.

**ETHICAL APPROVAL:**

Ethics Committee of Kırıkkale University, Institutional Review Board had approved the study. Date:16.05.2017 Number: 12/23

**PATIENTS’ CONSENT**

The consent forms were obtained from the parents of all patients.

**CONFLICT OF INTEREST:**

Authors declared no conflict of interest.

**AUTHORS’ CONTRIBUTIONS:**

ST: Design, literature search, data collection and processing, interpretation of data, writing the article.

AA, ATE: Literature search, data collection.

IK: Literature search, analysis and interpretation of data.

SN, OE: Studied the collected samples in biochemistry laboratory.

**REFERENCES**

1. Gawlik A, Such K, Dejnner A, Zachurzok A, Antosz A, Malecka-Tendera E. Subclinical Hypothyroidism in Children and Adolescents: Is It Clinically Relevant? Int J Endocrinol 2015; 2015:1-12.

2. Gallizzi R, Crisafulli C, Aversa T, Salzano G, De Luca F, Valenzise M, et al. Subclinical hypothyroidism in children: Is it always subclinical? Ital J Pediatr 2018; 44(1):25

3. Alpcan A, Törel Ergür A, Tursun S. Çocukluk çağının gizli tehlikesi: subklinik hipotiroidi. Ortadogu Med J 2017; 9(1):34-8.

4. Cremer C M, Jakob U. Oxidant sensing by reversible disulfide bond formation. J Biol Chem 2013; 288(37): 26489-96.

5. Seshadri RV, Sethi S, Gupta N, Agrawal P, Chander SR. Significance of ischemia-modified albumin as simple measure of oxidative stress and discriminatory ability in diabetic retinopathy. Literature review and meta-analysis. Retina 2016; 36(6):1049-57.

6. Hazini A, Cemek M, Isildak I, Alpdagtas S, Onul A, Unal Ş, et al. Investigation of ischemia modified albumin, oxidant and antioxidant markers in acute myocardial infarction. Postepy kardiol interwencyjne 2015; 11(4):298-303.

7. Gulpmak B, Tekin K, Sonmez K, Inanc M, Neselioğlu S, Erel O, et al. The significance of thiol/disulfide homeostasis and ischemia-modified albumin levels to assess the oxidative stress in patients with different stages of diabetes mellitus. Scand J Clin Lab Invest 2018; 78(1-2):136-42.

8. Bundak R, Furman A, Gunoz H, Darendeliler F, Bas F, Neyzi O. Body mass index references for Turkish children. Acta Paediatr 2006; 95(2):194-8.

9. Salerno M, Capalbo D, Cerbone M, De Luca F. Subclinical hypothyroidism in childhood - current knowledge and open issues. Nat Rev Endocrinol 2016; 12(12):734-46.

10. Erel O, Neselioğlu S. A novel and automated assay for thiol/disulphide homeostasis. Clin Biochem 2014; 47(18):326-32.

11. Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-
albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. *J Emerg Med* 2000; **19**(4):311-15.

12. Liguori I, Russo G, Curcio F, Bulli G, Aran L, Della-Morte D, et al. Oxidative stress, aging, and diseases. *Clin Interv Aging* 2018; **13**:757-72.

13. Sinha MK, Gaze DC, Tippins JR, Collinson PO, Kaski JC. Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. *Circulation* 2003; **107**(19):2403-5

14. Yang F, Ma L, Zhang L, Wang Y, Zhao C, Zhu W, et al. Association between serum lipoprotein-associated phospholipase A2, ischemic modified albumin and acute coronary syndrome: A cross-sectional study. *Heart Vessels* 2019; **34**(10):1608-14

15. Pan D, Li D. Role of ischemia-modified albumin in patients with acute decompensated heart failure. *Anadolu Kardiyol Derg* 2015; **15**(8):618-9.

16. Yavuz F, Biyik M, Asil M, Dertli R, Demir A, Polat H, et al. Serum ischemic modified albumin (IMA) concentration and IMA/albumin ratio in patients with hepatitis B-related chronic liver diseases. *Turkish J Med Sci* 2017; **47**(3):947-53.

17. Balamir I, Ates I, Topcuoglu C, Turhan T. Association of Endocan, Ischemia-Modified Albumin, and hsCRP Levels With Endothelial Dysfunction in Type 2 Diabetes Mellitus. *Angiology* 2018; **69**(7):609-16.

18. Huang QX, Ma J, Wang YS. Significance of preoperative ischemia-modified albumin in operable and advanced gastric cancer. *Cancer Biomark* 2018; **22**(3):477-85.

19. Doğan HO, Meriç Yılmaz F, Topçuoğlu C, Berker D, Koca Y. Investigation of the relationship between tsh and serum lipids in patients with subclinical hypothyroidism and euthyroid subjects. *Cumhur Med J* 2016; **38**:110-8.

20. Reddy SV, Suchitra MM, Pradeep V, Alok S, Suresh V, Bitla AR, et al. Ischemia-modified albumin levels in overt and subclinical hypothyroidism. *J Endocrinol Invest* 2015; **38**(8):885-90.

21. Erem C, Suleyman AK, Civan N, Mentese A, Nuhoglu İ, Uzun A, et al. The effect of L-thyroxine replacement therapy on ischemia-modified albumin and malondialdehyde levels in patients with overt and subclinical hypothyroidism. *Endocr Res* 2016; **41**(4):350-60.

22. Oncel M, Kiyici A, Onen S. Evaluation of the Relationship Between Ischemia-Modified Albumin Levels and Thyroid Hormone Levels. *J Clin Lab Anal* 2015; **29**(6):427-31.

23. Uçaktürk SA, Alşlık M, Uğur Ç, Elmaoğullari S, Mengen E, Erel Ö. Dynamic Thiol/Disulphide Homeostasis in Children and Adolescents with Non-Autoimmune Subclinical Hypothyroidism. *Med Princ Pract* 2018; **27**(1):44-8.

24. Ates I, Altay M, Yilmaz FM, Topcuoglu C, Neselioglu S, Erel O, et al. Dynamic thiol/disulfide homeostasis in patients with autoimmune subclinical hypothyroidism. *Endocr Res* 2016; **41**(4):343-9.

25. Cheserek MJ, Wu GR, Ntazinda A, Shi YH, Shen LY, Le GW. Association between Thyroid Hormones, Lipids and Oxidative Stress Markers in Subclinical Hypothyroidism. *J Med Biochem* 2015; **34**(3):323-31.